Efficacy/ Safety of DNN.22.17.036 in Male Patients With Pattern Hair Loss

Last updated: April 4, 2024
Sponsor: Ache Laboratorios Farmaceuticos S.A.
Overall Status: Active - Not Recruiting

Phase

4

Condition

Alopecia

Hair Loss

Treatment

DNN.22.17.036

10573048700

Clinical Study ID

NCT06355856
ACH-PNT-04(01/22)
  • Ages 25-60
  • Male

Study Summary

Evaluation of the efficacy and safety of DNN.22.17.036 versus 10573048700 in the treatment of male pattern hair loss.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Ability to understand and consent to participate in this clinical research, expressedby signing the Informed Consent Form (ICF)
  • Male participants age 25 or older and 60 age or younger
  • Participants who have an intact scalp in the area of product analysis
  • Participants with androgenetic alopecia (AGA) with AGA Norwood-Hamilton Scale > II
  • Participants with at least 20% telogen effluvium of evaluated by Tricholab

Exclusion

Exclusion Criteria:

  • Participants who have used immunosuppressants in the 3 months prior to signing the ICF
  • Participants with other causes of hair loss or scalp dermatoses
  • Participants who have received hair loss treatment in the last 6 months
  • Participants with uncontrolled medical conditions, kidney and liver disease
  • Participants with a history of hair transplantation, malignancy, hematologicdisorders, thyroid dysfunction, malnutrition, and other dermatologic disorders thatcontribute to hair loss

Study Design

Total Participants: 196
Treatment Group(s): 2
Primary Treatment: DNN.22.17.036
Phase: 4
Study Start date:
April 01, 2024
Estimated Completion Date:
May 31, 2025